Baxter Recalls One Lot of Nitroglycerin in 5% Dextrose Injection - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Baxter Recalls One Lot of Nitroglycerin in 5% Dextrose Injection

Baxter has issued a voluntary recall of one lot of nitroglycerin in 5% dextrose injection after particulate matter was found in one vial. This recall is being conducted with the knowledge of the US FDA.

Injection of particulate matter can lead to blockage of blood vessels. It can also cause inflammation, particularly in the lungs, and local irritation of blood vessels due to the presence of foreign material. No adverse events associated with this issue have been reported to date.

Baxter's nitroglycerin in 5% dextrose injection is packaged in 250 mL glass containers, with 12 glass containers per carton. The affected product code is 1A0694, and the affected lot number is G105197. Products affected by this recall were distributed in Colombia, Saudi Arabia and the United States between January 17, 2013, and October 10, 2013. Baxter has notified its customers not to use product from the recalled lot and to return all affected product.

Source: Baxter


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here